Altimmune, Inc.

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Role: lead

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

Role: lead

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Role: lead

RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Role: lead

NasoShield Study of Safety and Immunogenicity

Role: lead

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Role: lead

NasoShield in Healthy Adults to Study Safety and Immunogenicity

Role: lead

Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

Role: lead

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

Role: lead

Study of the Safety and Immunogenicity of NasoVAX Extension

Role: lead

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Role: lead

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

Role: lead

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Role: lead

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Role: lead

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Role: lead

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Role: lead

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Role: lead

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Role: lead

Immune Response Following Seasonal Influenza Vaccination

Role: lead